Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...

that are combined into the CagriSema injection. "The protocol of the new planned trial will come out in 2025," the spokesperson said. Earlier on Friday, Novo said CagriSema helped patients cut ...

Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped overweight patients cut their ...

Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of its next-generation obesity drug candidate CagriSema did not reach the ...

Novo Nordisk’s shares fell sharply on Friday as disappointing results from tests of its latest obesity drug wiped about €90bn off the valuation of Europe’s largest company by market capitalisation.

CagriSema is a fixed-dose combination of a ... Recently, the FDA removed Lilly’s tirzepatide injection products from the drug shortage list after determining that Lilly’s supply is currently ...

such as CagriSema and Zepbound. Also Read: Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide’s Impact on Bone Density The analyst writes that MariTide ...

Investing.com -- Novo Nordisk (CSE: NOVOb ) shares jumped over 9% on Monday, despite the company’s disappointing results for ...

The CagriSema news boosted competitors ... Akash Tewari said the results Friday put Lilly "in the driver's seat for injection portfolio and potential oral if orfo works." Anjalee Khemlani is ...

The Danish drugmaker reported weight-loss data for experimental obesity injection CagriSema that fell short of its expectations in a clinical study. “This is no doubt a painful result ...

CagriSema is a weekly injection combining semaglutide, which is the active ingredient in Wegovy and mimics the gut hormone GLP-1, and a separate molecule called cagrilintide that mimics the ...